Evaluation of Rivaroxaban Exposure via
Anti-Xa Levels During VTE Prophylaxis
in Hospitalized Patients

Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients

Rivaroxaban was FDA-approved in 2019 for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients. Little to no published data is available to determine the level of correlation between rivaroxaban drug concentration and UFH/LMWH calibrated anti-Xa assays at VTE prophylactic dos...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kaitlin Blotske PharmD, Toral Patel PharmD, BCPS, Toby Trujillo PharmD, FCCP, FAHA, BCPS, Matthew Marlar MLS (ASCP), Stuart Lind MD, Henry Kramer MD, Kathryn Hassell MD, Tyree H. Kiser PharmD, FCCM, FCCP, BCCCP, BCPS
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-02-01
Series:	Clinical and Applied Thrombosis/Hemostasis
Online Access:	https://doi.org/10.1177/10760296251319961
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A Retrospective, Single-Center Assessment of Changes in Pain, Agitation, and Delirium Management Before and During the COVID-19 Pandemic
by: Rachel L. Winner, PharmD, BCCCP, et al.
Published: (2025-01-01)

Comparison of Direct Oral Anticoagulants for Treatment of Cerebral Venous Thrombosis – A Retrospective Cohort Study
by: Paul Phan PharmD, et al.
Published: (2025-01-01)

Cost-Consequence Analysis of Apixaban Versus Rivaroxaban for Managing Patients with Venous Thromboembolism in Saudi Arabia
by: Abdulaali R. Almutairi PhD, et al.
Published: (2025-02-01)

Homologous In-Radiolabeled Platelet Survival and Sequestration Exploration for Refractory Immunologic Thrombocytopenic purpura in Children: A Strategy to Avoid Unnecessary Splenectomy
by: Julien Dubois PharmD, et al.
Published: (2024-11-01)

Metabolic and Bariatric Surgery Utilization Trends in the United States: Evidence From 2012 to 2021 National Electronic Medical Records Network
by: Abdulrahman Alsuhibani, PharmD, MSc, PhD, et al.
Published: (2023-12-01)

Tenecteplase vs Reteplase in Patients with Acute ST-Elevation Myocardial Infarction: A Retrospective Cohort Study
by: Adham Mohamed PharmD, et al.
Published: (2025-02-01)

Examining Symptom Management and Quality of Life of Loop Diuretic-Induced Overactive Bladder Among Heart Failure Patients: Physician and Patient Perspectives
by: Xin Pan PharmD, MPH, et al.
Published: (2025-02-01)

Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States
by: Tahuanty A. Pena, MD, MS, et al.
Published: (2025-02-01)

A large pruritic plaque in a patient with 2 kidney transplants
by: Chiel F. Ebbelaar, MD, PharmD, et al.
Published: (2025-03-01)

Reply
by: Denis Vincent, MD, PhD, et al.
Published: (2025-05-01)

Association Between Opioid-Related Mortality and History of Surgical Procedure: A Population-Based Case-Control Study
by: Mhd Wasem Alsabbagh, BScPhm, PhD, et al.
Published: (2024-06-01)

Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil
by: Daniel Lachant, DO, et al.
Published: (2025-05-01)

Corticosteroid use beyond 1-year post heart transplantation is associated with worse outcomes: A contemporary analysis of the ISHLT registry
by: Abhishek Jaiswal, MD, et al.
Published: (2025-05-01)

Health State Utility Values in Children and Adolescents with Disabilities: A Systematic Review
by: Lucy Kanya, PhD, et al.
Published: (2025-03-01)

Environmental Sustainability Initiatives in the Operating Room: A Scoping Review
by: Emre Gorgun, MD, et al.
Published: (2024-09-01)

Hydroxocobalamin for the treatment of vasoplegia after lung transplantation: A case series
by: Anh Nguyen, MD, PhD, et al.
Published: (2025-02-01)

Artificial Liver Support Systems in Acute Liver Failure and Acute-on-Chronic Liver Failure: Systematic Review and Meta-Analysis
by: Robert S. Brown, Jr, MD, MPH, et al.
Published: (2025-01-01)

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
by: Arianna Marinello, MD, et al.
Published: (2025-03-01)

Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization
by: Ian S. Jaffe, BS, et al.
Published: (2025-02-01)

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01)

Lung transplant outcomes for recipients with alpha-1 antitrypsin deficiency, by use of alpha-1 antitrypsin augmentation therapy
by: Atharv V. Oak, MEng, et al.
Published: (2025-02-01)

Visual Mapping of Operating Theater Team Dynamics and Communication for Reflexive Feedback and Surgical Practice Optimization
by: Surya Surendran, MA, et al.
Published: (2024-09-01)

SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) WITH LOW DOSE APIXABAN OR RIVAROXABAN: RESULTS FROM A PATIENT POPULATION WITH MORE THAN 2 YEARS OF MEDIAN FOLLOW-UP
by: Alessandro Laganà, et al.
Published: (2024-02-01)

Gestational weight gain and increased risk of cesarean delivery across body mass index categoriesAJOG Global Reports at a Glance
by: Pearl A. McElfish, PhD, et al.
Published: (2025-02-01)

Defining the Need for Causal Inference to Understand the Impact of Social Determinants of Health: A Primer on Behalf of the Consortium for the Holistic Assessment of Risk in Transplantation (CHART)
by: Nrupen A. Bhavsar, PhD, et al.
Published: (2023-12-01)

Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites
by: Thomas Kayser, MD, BS, et al.
Published: (2025-05-01)

Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban
by: Qianxing Zhou, et al.
Published: (2011-01-01)

American Society for Gastrointestinal Endoscopy guideline on gastrostomy feeding tubes: methodology and review of evidence
by: Divyanshoo Rai Kohli, MD, et al.
Published: (2025-01-01)

Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
by: Margaret Stalker, MD, et al.
Published: (2025-01-01)

Clinical Scenarios for Discordant Anti-Xa
by: Jesus Vera-Aguilera, et al.
Published: (2016-01-01)

HEalth-Related Quality of Life-Intervention in Survivors of Breast and Other Cancers Experiencing Cancer-Related Fatigue and Associated Cognitive Symptoms Using TraditionAL Chinese Medicine: The ‘HERBAL’ Trial
by: Alexandre Chan PharmD, et al.
Published: (2025-01-01)

The Multifaceted Roles of Myrrha in the Treatment of Breast Cancer: Potential Therapeutic Targets and Promises
by: Anwar Shams MD, MSc, PhD, et al.
Published: (2024-12-01)

Rivaroxaban and Hemostasis in Emergency Care
by: Jürgen Koscielny, et al.
Published: (2014-01-01)

Life-Threatening Hemopericardium Associated with Rivaroxaban
by: Sijan Basnet, et al.
Published: (2017-01-01)

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
by: Dane D. Gruenebaum, et al.
Published: (2014-01-01)

BTT-ECMO Trends and Outcomes Under Revised Heart Allocation System
by: Aniket S. Rali, MD, FACC, FCCP, et al.
Published: (2025-02-01)

SARS-CoV-2 Infection-Associated Aortic Thrombosis Treated with Oral Factor Xa Inhibition
by: Alena Strýčková, et al.
Published: (2022-01-01)

Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy
by: Jonathan M. Yaghoubian, et al.
Published: (2017-01-01)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
by: Muhammed Sherid, et al.
Published: (2016-01-01)

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
by: Tung Phi Nguyen, et al.
Published: (2021-01-01)